Digestive and Liver Disease
Volume 41, Issue 8 , Pages 591-598 , August 2009

Significance of increased expression of decoy receptor 3 in chronic liver disease

  • S. Kim

      Affiliations

    • BioPowerTech, Tuscaloosa, AL 35406, USA
    • Corresponding Author InformationCorresponding author at: 4734 Bluegrass Pkwy, Tuscaloosa, AL 35406, USA. Tel.: +1 205 345 2512.
    • ,
  • V. Kotoula

      Affiliations

    • Department of Pathology, School of Medicine, Aristotle University, 54006 Thessaloniki, Greece
    • ,
  • P. Hytiroglou

      Affiliations

    • Department of Pathology, School of Medicine, Aristotle University, 54006 Thessaloniki, Greece
    • ,
  • D. Zardavas

      Affiliations

    • Department of Pathology, School of Medicine, Aristotle University, 54006 Thessaloniki, Greece
    • ,
  • L. Zhang

      Affiliations

    • BioPowerTech, Tuscaloosa, AL 35406, USA

Received 8 August 2008 ,Accepted 20 November 2008.

References 

  1. Akazawa Y, Gores GJ. Death receptor-mediated liver injury. Semin Liver Dis. 2007;27:327–328
  2. Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S. Essential roles of the Fas ligand in the development of hepatitis. Nat Med. 1997;3:409–413
  3. Ding WX, Yin XM. Dissection of the multiple mechanisms of TNF-alpha-induced apoptosis in liver injury. J Cell Mol Med. 2004;8:445–454
  4. Papakyriakou P, Tzardi M, Valatas V, Kanavaros P, Karydi E, Notas G, et al. Apoptosis and apoptosis related proteins in chronic viral liver disease. Apoptosis. 2002;7:133–141
  5. Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature. 1998;396:699–703
  6. Fujita Y, Sakakura C, Shimomura K, Nakanishi M, Yasuoka R, Aragane H, et al. Chromosome arm 20q gains and other genomic alterations in esophageal squamous cell carcinoma, as analyzed by comparative genomic hybridization and fluorescence in situ hybridization. Hepatogastroenterology. 2003;50:1857–1863
  7. Chen J, Zhang L, Kim S. Quantification and detection of DcR3, a decoy receptor in TNFR family. J Immunol Methods. 2004;285:63–70
  8. Yu KY, Kwon B, Ni J, Zhai Y, Ebner R, Kwon BS. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem. 1999;274:13733–13736
  9. Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B, et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity. 2002;16:479–492
  10. Bai C, Connolly B, Metzker ML, Hilliard CA, Liu X, Sandig V, et al. Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc Natl Acad Sci USA. 2000;97:1230–1235
  11. Roth W, Isenmann S, Nakamura M, Platten M, Wick W, Kleihues P, et al. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand induced apoptosis and chemotaxis. Cancer Res. 2001;61:2759–2765
  12. Gill RM, Hunt JS. Soluble receptor (DcR3) and cellular inhibitor of apoptosis-2 (cIAP-2) protect human cytotrophoblast cells against LIGHT-mediated apoptosis. Am J Pathol. 2004;165:309–317
  13. Connolly K, Cho YH, Duan R, Fikes J, Gregorio T, LaFleur DW, et al. In vivo inhibition of Fas ligand mediated killing by TR6, a Fas ligand decoy receptor. J Pharmacol Exp Ther. 2001;298:25–33
  14. Wortinger MA, Foley JW, Larocque P, Witcher DR, Lahn M, Jakubowski JA, et al. Fas ligand-induced murine pulmonary inflammation is reduced by a stable decoy receptor 3 analogue. Immunology. 2003;110:225–233
  15. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1:431–435
  16. Kim S, Fotiadu A, Kotoula V. Increased expression of soluble decoy receptor 3 in acutely inflamed intestinal epithelia. Clin Immunol. 2005;115:286–294
  17. Xiao JC, Jin XL, Ruck P, Adam A, Kaiserling E. Hepatic progenitor cells in human liver cirrhosis: immunohistochemical, electron microscopic and immunofluorencence confocal microscopic findings. World J Gastroenterol. 2004;10:1208–1211
  18. Shen HW, Gao SL, Wu YL, Peng SY. Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis. World J Gastroenterol. 2005;11:5926–5930
  19. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002;298:1911–1912
  20. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA. 1995;92:7686–7689
  21. Duncia JV, Santella JB, Higley CA, Pitts WJ, Wityak J, Frietze WE, et al. MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products. Bioorg Med Chem Lett. 1998;8:2839–2844
  22. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem. 1998;273:18623–18632
  23. Bennett BL, Sasaki DT, Murray BW, O’Leary EC, Sakata ST, Xu W, et al. SP600125, an anthrapyrazolone inhibitor of Jun N terminal kinase. Proc Natl Acad Sci USA. 2001;98:13681–13686
  24. Kalmes A, Deou J, Clowes AW, Daum G. Raf-1 is activated by the p38 mitogen-activated protein kinase inhibitor, SB203580. FEBS Lett. 1999;444:71–74
  25. Guo LL, Xiao S, Guo Y. Activation of transcription factors NF-kappaB and AP-1 and their relations with apoptosis associated-proteins in hepatocellular carcinoma. World J Gastroenterol. 2005;11:3860–3865
  26. Hayashi N, Mita E. Fas system and apoptosis in viral hepatitis. J Gastroenterol Hepatol. 1997;12:S223–S226
  27. Hayashi N, Mita E. Involvement of Fas system-mediated apoptosis in pathogenesis of viral hepatitis. J Viral Hepat. 1999;6:357–365
  28. Chen NL, Bai L, Li L, Chen PL, Zhang C, Liu CY, et al. Apoptosis pathway of liver cells in chronic hepatitis. World J Gastroenterol. 2004;10:3201–3214
  29. Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel W, et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med. 1995;182:1223–1230
  30. Zhao Y, Li S, Childs EE, Kuharsky DK, Yin XM. Activation of pro-death Bcl-2 family proteins and mitochondria apoptosis pathway in tumor necrosis factor-alpha-induced liver injury. J Biol Chem. 2001;276:27432–27440
  31. Tsamandas AC, Thomopoulos K, Gogos C, Tepetes K, Kourelis T, Ravazoula P, et al. Expression of bcl-2 oncoprotein in cases of acute and chronic viral hepatitis type B and type C: a clinicopathologic study. Dig Dis Sci. 2002;47:1618–1624
  32. Frommel TO, Yong S, Zarling EJ. Immunohistochemical evaluation of Bcl-2 gene family expression in liver of hepatitis C and cirrhotic patients: a novel mechanism to explain the high incidence of hepatocarcinoma in cirrhotics. Am J Gastroenterol. 1999;94:178–182
  33. Kim S, McAuliffe WJ, Zaritskaya LS, Moore PA, Zhang L, Nardelli B. Selective induction of tumor necrosis receptor factor 6/decoy receptor 3 release by bacterial antigens in human monocytes and myeloid dendritic cells. Infect Immun. 2004;72:89–93
  34. Hsu SC, Gavrilin MA, Tsai MH, Han J, Lai MZ. p38 mitogen-activated protein kinase is involved in Fas ligand expression. J Biol Chem. 1999;274:25769–25776
  35. Iyoda K, Sasaki Y, Horimoto M, Toyama T, Yakushijin T, Sakakibara M, et al. Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma. Cancer. 2003;97:3017–3026
  36. Brancho D, Tanaka N, Jaeschke A, Ventura JJ, Kelkar N, Tanaka Y, et al. Mechanism of p38 MAP kinase activation in vivo. Genes Dev. 2003;17:1969–1978
  37. Theise ND, Saxena R, Portmann BC, Thung SN, Yee H, Chiriboga L, et al. The canals of Hering and hepatic stem cells in humans. Hepatology. 1999;30:1425–1433
  38. Roskams TA, Libbrecht L, Desmet VJ. Progenitor cells in diseased human liver. Semin Liver Dis. 2003;23:385–396
  39. Lowes KN, Brennan BA, Yeoh GC, Olynyk JK. Oval cell numbers in human chronic liver diseases are directly related to disease severity. Am J Pathol. 1999;154:537–541
  40. Theise ND, Yao JL, Harada K, Hytiroglou P, Portmann B, Thung SN, et al. Hepatic ‘stem cell’ malignancies in adults: four cases. Histopathology. 2003;43:263–271
  41. Knight B, Matthews VB, Akhurst B, Croager EJ, Klinken E, Abraham LJ, et al. Liver inflammation and cytokine production, but not acute phase protein synthesis, accompany the adult liver progenitor (oval) cell response to chronic liver injury. Immunol Cell Biol. 2005;83:364–374
  42. Friedman SL. Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol. 2004;1:98–105

PII: S1590-8658(08)00858-X

doi: 10.1016/j.dld.2008.11.019

Digestive and Liver Disease
Volume 41, Issue 8 , Pages 591-598 , August 2009

Article Tools

* Image Usage & Resolution